Core Insights - Cabaletta Bio, Inc. is a clinical-stage biotechnology company focused on developing curative targeted cell therapies for autoimmune diseases [2] - The company will participate in several investor conferences in November and December 2025, providing opportunities for investor engagement [1][3] Company Overview - Cabaletta Bio utilizes the CABA™ platform, which includes two strategies aimed at developing engineered T cell therapies for autoimmune diseases [2] - The lead strategy, CARTA, focuses on the investigational therapy rese-cel, a fully human CD19-CAR T cell therapy [2] - Rese-cel is currently being evaluated in the RESET™ clinical development program across multiple therapeutic areas, including rheumatology, neurology, and dermatology [2] Upcoming Events - The company will host a webcasted fireside chat at the Guggenheim's 2nd Annual Healthcare Innovation Conference on November 11, 2025 [3] - Additional events include a fireside chat at the TD Cowen Immunology & Inflammation Summit on November 13, 2025, and the Jefferies Global Healthcare Conference on November 17, 2025 [3] - The company will also participate in the 8th Annual Evercore Healthcare Conference on December 2, 2025, and Citi's 2025 Global Healthcare Conference on December 3, 2025 [3]

Core Viewpoint - Cabaletta Bio, Inc. has initiated an underwritten public offering of its common stock and accompanying warrants, aiming to raise capital for its clinical-stage biotechnology operations focused on autoimmune diseases [1][2]. Group 1: Offering Details - The public offering includes shares of common stock and pre-funded warrants, with an option for underwriters to purchase an additional 15% of the offering [1][2]. - The offering is expected to close around June 12, 2025, subject to market conditions and customary closing conditions [2]. Group 2: Company Overview - Cabaletta Bio is a clinical-stage biotechnology company dedicated to developing curative targeted cell therapies for autoimmune diseases [5]. - The company’s CABA™ platform employs two strategies to advance engineered T cell therapies, with a focus on the CARTA strategy and its lead investigational therapy, rese-cel [5]. - Rese-cel is currently being evaluated in the RESET™ clinical development program, which spans multiple therapeutic areas including rheumatology, neurology, and dermatology [5].